MCID: CTN004
MIFTS: 41

Cutaneous Fibrous Histiocytoma

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Cutaneous Fibrous Histiocytoma

MalaCards integrated aliases for Cutaneous Fibrous Histiocytoma:

Name: Cutaneous Fibrous Histiocytoma 12 50 14 69
Dermatofibroma 12 50 52
Fibrohistiocytic Tumor 12 69
Benign Cutaneous Fibrous Histiocytoma 12
Dermatofibroma, No Icd-O Subtype 12
Fibrous Histiocytoma of Skin 12
Sclerosing Angioma of Skin 12
Fibrohistiocytic Neoplasm 12
Fibrous Xanthoma of Skin 12
Pleomorphic Fibroma 12
Dermatofibroma Nos 12
Sclerosing Angioma 12

Classifications:



Summaries for Cutaneous Fibrous Histiocytoma

NIH Rare Diseases : 50 dermatofibroma is a common benign skin nodule. it frequently develops on the extremities (most often the lower legs). although it is generally not associated with any signs or symptoms, some affected people may experience itching and/or tenderness. dermatofibromas are found in people of all ages and ethnicity and are more commonly diagnosed in women than men. the underlying cause of dermatofibroma is currently unknown. treatment is generally not required, but if symptoms are present, the lesion can be surgically removed. last updated: 3/19/2017

MalaCards based summary : Cutaneous Fibrous Histiocytoma, also known as dermatofibroma, is related to histiocytoma and malignant skin fibrous histiocytoma. An important gene associated with Cutaneous Fibrous Histiocytoma is F13A1 (Coagulation Factor XIII A Chain), and among its related pathways/superpathways are Cytoskeletal Signaling and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Cutaneous Fibrous Histiocytoma

Diseases related to Cutaneous Fibrous Histiocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
id Related Disease Score Top Affiliating Genes
1 histiocytoma 30.5 ACTC1 DES VIM
2 malignant skin fibrous histiocytoma 11.1
3 undifferentiated pleomorphic sarcoma 10.9
4 infantile scoliosis 10.6 DES VIM
5 neuromuscular junction disease 10.6 DES F13A1
6 classic mast cell leukemia 10.6 F13A1 S100B
7 cortical blindness 10.6 F13A1 VIM
8 lymphocytic infiltrate of jessner 10.6 DES VIM
9 intellectual disability-polydactyly-uncombable hair syndrome 10.6 DES VIM
10 cataract congenital autosomal dominant 10.6 DES F13A1
11 hemangioma 10.6 F13A1 VIM
12 pineal region yolk sac tumor 10.6 DES VIM
13 mannose-binding lectin protein deficiency 10.6 DES VIM
14 cellular ependymoma 10.6 DES VIM
15 spleen cancer 10.6 DES S100B
16 immune-mediated encephalomyelitis 10.6 S100B VIM
17 sparse hair-short stature-skin anomalies syndrome 10.6 DES S100B
18 mucinous ovarian cystadenoma 10.6 DES S100B
19 space motion sickness 10.6 DES VIM
20 childhood pleomorphic rhabdomyosarcoma 10.5 DES VIM
21 neurogenic thoracic outlet syndrome 10.5 S100B VIM
22 reticular pattern testicular yolk sac tumor 10.5 S100B VIM
23 pancreatic intraductal papillary-colloid carcinoma 10.5 S100B VIM
24 rectal neoplasm 10.5 DES VIM
25 extraskeletal mesenchymal chondrosarcoma 10.5 DES VIM
26 lice infestation 10.5 S100B VIM
27 spondyloepimetaphyseal dysplasia, isidor type 10.5 DES VIM
28 ganglioglioma 10.5 S100B VIM
29 anaplastic oligodendroglioma 10.5 S100B VIM
30 myoepithelial carcinoma 10.5 DES VIM
31 malignant breast melanoma 10.5 S100B VIM
32 urethral urothelial papilloma 10.4 CD163 VIM
33 prostate disease 10.4 S100B VIM
34 oligomeganephronic renal hypoplasia 10.4 S100B VIM
35 tracheo-esophageal fistula-hypospadias syndrome 10.4 ACTC1 F13A1
36 chondroblastoma 10.4 DES VIM
37 scn8a encephalopathy 10.4 ACTC1 F13A1
38 vulvar keratoacanthoma-like carcinoma 10.4 S100B VIM
39 hip subluxation 10.4 S100B VIM
40 marfanoid habitus-inguinal hernia-advanced bone age syndrome 10.4 ACTC1 DES
41 lymphocytic hypophysitis 10.4 ACTC1 VIM
42 fibrous histiocytoma 10.4
43 oromandibular dystonia 10.3 PDGFB VIM
44 gastric signet ring cell adenocarcinoma 10.3 ACTC1 VIM
45 iridogoniodysgenesis and skeletal anomalies 10.3 ACTC1 VIM
46 rrm2b-related mitochondrial dna depletion syndrome 10.3 CD163 S100B
47 acute allergic serous otitis media 10.3 S100B VIM
48 punctate palmoplantar keratoderma type 2 10.3 ACTC1 DES
49 liver angiosarcoma 10.3 ACTC1 DES
50 localized pulmonary fibrosis 10.3 ACTC1 S100B

Graphical network of the top 20 diseases related to Cutaneous Fibrous Histiocytoma:



Diseases related to Cutaneous Fibrous Histiocytoma

Symptoms & Phenotypes for Cutaneous Fibrous Histiocytoma

MGI Mouse Phenotypes related to Cutaneous Fibrous Histiocytoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 ACTC1 CD163 DES F13A1 MMP11 PDGFB
2 homeostasis/metabolism MP:0005376 9.56 ACTC1 CD163 DES F13A1 MMP11 PDGFB
3 muscle MP:0005369 9.02 ACTC1 CD163 DES PDGFB VIM

Drugs & Therapeutics for Cutaneous Fibrous Histiocytoma

Drugs for Cutaneous Fibrous Histiocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved Phase 3 50-76-0 2019 457193
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Lenograstim Approved Phase 3,Phase 2 135968-09-1
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Isophosphamide mustard Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Antimitotic Agents Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Antirheumatic Agents Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25
Indinavir Approved Phase 2 150378-17-9 5362440
26
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
27
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
30
Bevacizumab Approved, Investigational Phase 2 216974-75-3
31
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
34
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
35
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
37
nivolumab Approved Phase 2,Phase 1 946414-94-4
38
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
39
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
40
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
41
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
44
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
45
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
46
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
47
Saracatinib Investigational Phase 2 379231-04-6
48 Soblidotin Investigational Phase 2 149606-27-9
49
Camptothecin Experimental Phase 2 7689-03-4
50 Exatecan Investigational Phase 2 171335-80-1

Interventional clinical trials:

(show top 50) (show all 65)

id Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
27 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
28 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
30 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
35 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
36 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
37 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
38 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
39 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
40 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
41 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
42 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
43 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Active, not recruiting NCT01962103 Phase 1, Phase 2 nab-paclitaxel
44 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2 Alisertib
45 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
46 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
47 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Suspended NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
48 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Gemcitabine and Docetaxel in Combination with Pazopanib
49 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
50 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib

Search NIH Clinical Center for Cutaneous Fibrous Histiocytoma

Genetic Tests for Cutaneous Fibrous Histiocytoma

Anatomical Context for Cutaneous Fibrous Histiocytoma

MalaCards organs/tissues related to Cutaneous Fibrous Histiocytoma:

39
Skin, Bone, Lung, Endothelial, Liver, Testis, Brain

Publications for Cutaneous Fibrous Histiocytoma

Articles related to Cutaneous Fibrous Histiocytoma:

(show all 15)
id Title Authors Year
1
Metastasizing "benign" cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. ( 23426120 )
2013
2
Atypical cutaneous fibrous histiocytoma: an unusual and misleading variant of fibrous histiocytoma. ( 22937387 )
2011
3
A study of monocytic and dendritic cell markers in benign cutaneous fibrous histiocytoma (dermatofibroma). ( 18462367 )
2008
4
A unique biphasic variant of cutaneous fibrous histiocytoma with a storiform pattern and intralesional pigmented melanocytes: "storiform melano-fibrous histiocytoma". ( 18474466 )
2008
5
The value of immunohistochemistry in atypical cutaneous fibrous histiocytoma. ( 15365367 )
2004
6
Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). ( 12139632 )
2002
7
Aneurysmal fibrous histiocytoma: an unusual variant of cutaneous fibrous histiocytoma. ( 10461644 )
1999
8
Recurring atypical ("pseudosarcomatous") cutaneous fibrous histiocytoma. ( 9649666 )
1998
9
Cutaneous fibrous histiocytoma. ( 9158319 )
1997
10
Cutaneous fibrous histiocytoma with osteoclast-like giant cells. ( 8863988 )
1996
11
Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. ( 8017561 )
1994
12
Palisading cutaneous fibrous histiocytoma. An immunohistochemical study demonstrating differentiation from dermal dendrocytes. ( 8311187 )
1993
13
Atypical, cutaneous fibrous histiocytoma with early metastasis. ( 3012378 )
1986
14
Palisading cutaneous fibrous histiocytoma. ( 3029199 )
1986
15
Atypical cutaneous fibrous histiocytoma. ( 3028197 )
1986

Variations for Cutaneous Fibrous Histiocytoma

Expression for Cutaneous Fibrous Histiocytoma

Search GEO for disease gene expression data for Cutaneous Fibrous Histiocytoma.

Pathways for Cutaneous Fibrous Histiocytoma

Pathways related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.92 ACTC1 DES VIM
2 11.03 PDGFB S100B VIM
3
Show member pathways
10.81 DES VIM
4 10.66 ACTC1 DES VIM

GO Terms for Cutaneous Fibrous Histiocytoma

Cellular components related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 8.8 MMP11 PDGFB VIM

Biological processes related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 8.96 DES VIM
2 muscle filament sliding GO:0030049 8.8 ACTC1 DES VIM

Molecular functions related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 8.92 DES PDGFB S100B VIM

Sources for Cutaneous Fibrous Histiocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....